Need — SCI

The Market

• +$210B spent on cancer treatment in U.S. (2023), spend expected to exceed $245B by 2030 – American Assoc. for Cancer Research

• +1.9M new cancer cases diagnosed (2023) - American Cancer Society

• Cancer is the 2nd leading cause of death in U.S – Centers for Disease Control

• Medicare & Medicaid coverage & reimbursement increasing year-over-year.

• U.S. Market is underserved with only 49 PT facilities currently in operation –

Market need is 300 facilities to treat today’s cancer patients.

  
    Largest Institutional Holders of Proton
Therapy Bonds
  
    Nuveen (TIAA)
    Invesco
  
    Blackrock
    T.Rowe Price
  
    Allianz/Pimco
    State Street
  
    Capital Research
    First Trust
  
    Federated
    SEI
  
    Prudential
    Alpine Woods
  
    Northern Trust
    BNY Mellon

Largest Institutional Holders of Proton Therapy Bonds
Nuveen (TIAA)	Invesco
Blackrock	T.Rowe Price
Allianz/Pimco	State Street
Capital Research	First Trust
Federated	SEI
Prudential	Alpine Woods
Northern Trust	BNY Mellon

Market Strategy

We target sustainable, underserved markets with positive population and economic stability, providing cancer treatment to patients via referral from ALL regional health-care providers. We are not tied to just one network or provider. Direct to patient marketing is key.